-
1
-
-
3042704660
-
Medullary thyroid carcinoma
-
Cohen EG, Shaha AR, Rinaldo A, Devaney KO, Ferlito A. Medullary thyroid carcinoma. Acta Otolaryngol. 2004;124: 544-57.
-
(2004)
Acta Otolaryngol
, vol.124
, pp. 544-557
-
-
Cohen, E.G.1
Shaha, A.R.2
Rinaldo, A.3
Devaney, K.O.4
Ferlito, A.5
-
2
-
-
58149239805
-
Medullary thyroid cancer: Early detection and novel treatments
-
Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol. 2009;21: 5-10.
-
(2009)
Curr Opin Oncol
, vol.21
, pp. 5-10
-
-
Roman, S.1
Mehta, P.2
Sosa, J.A.3
-
3
-
-
79851513758
-
Medullary thyroid cancer: An update of new guidelines and recent developments
-
Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments. Curr Opin Oncol. 2011;23: 22-7.
-
(2011)
Curr Opin Oncol
, vol.23
, pp. 22-27
-
-
Wu, L.S.1
Roman, S.A.2
Sosa, J.A.3
-
4
-
-
40749092887
-
Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma
-
RufiniV, Castaldi P, Treglia G, Perotti G, GrossMD, Al-Nahhas A, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother. 2008;62: 139-46.
-
(2008)
Biomed Pharmacother
, vol.62
, pp. 139-146
-
-
Rufiniv Castaldi, P.1
Treglia, G.2
Perotti, G.3
Grossmd Al-Nahhas, A.4
-
5
-
-
80051711134
-
Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: Fluorodeoxyglucose and nonfluorodeoxyglucose tracers
-
Wong KK, Arabi M, Zerizer I, Al-Nahhas A, Rubello D, GrossMD. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl Med Commun. 2011;32: 764-81.
-
(2011)
Nucl Med Commun
, vol.32
, pp. 764-781
-
-
Wong, K.K.1
Arabi, M.2
Zerizer, I.3
Al-Nahhas, A.4
Rubello, D.5
Gross, M.D.6
-
7
-
-
84862201270
-
How to treat a signal? Current basis for RETgenotype- oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer
-
Prazeres H, Torres J, Rodrigues F, Couto JP, Vinagre J, Sobrinho- Simoes M, et al. How to treat a signal? Current basis for RETgenotype- oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer. J Thyroid Res. 2011;2011: 678357.
-
(2011)
J Thyroid Res
, vol.2011
, pp. 678357
-
-
Prazeres, H.1
Torres, J.2
Rodrigues, F.3
Couto, J.P.4
Vinagre, J.5
Sobrinho- Simoes, M.6
-
8
-
-
77955393886
-
The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors
-
Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010;31: 578-99.
-
(2010)
Endocr Rev
, vol.31
, pp. 578-599
-
-
Ye, L.1
Santarpia, L.2
Gagel, R.F.3
-
9
-
-
67749130797
-
Medullary thyroid cancer: Management guidelines of the American Thyroid Association
-
Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19: 565-612.
-
(2009)
Thyroid
, vol.19
, pp. 565-612
-
-
Kloos, R.T.1
Eng, C.2
Evans, D.B.3
Francis, G.L.4
Gagel, R.F.5
Gharib, H.6
-
10
-
-
78649924923
-
Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?
-
discussion 1309-10
-
Grubbs EG, Waguespack SG, Rich TA, Xing Y, Ying AK, Evans DB, et al. Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A? Surgery. 2010;148: 1302-9. discussion 1309-10.
-
(2010)
Surgery
, vol.148
, pp. 1302-1309
-
-
Grubbs, E.G.1
Waguespack, S.G.2
Rich, T.A.3
Xing, Y.4
Ying, A.K.5
Evans, D.B.6
-
11
-
-
77953007830
-
Medullary carcinoma
-
Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, et al. Medullary carcinoma. J Natl Compr Canc Netw. 2010;8: 512-30.
-
(2010)
J Natl Compr Canc Netw
, vol.8
, pp. 512-530
-
-
Tuttle, R.M.1
Ball, D.W.2
Byrd, D.3
Daniels, G.H.4
Dilawari, R.A.5
Doherty, G.M.6
-
12
-
-
4844221091
-
Role of CT/111In-octreotide SPECT digital fusion imaging in the localization of loco-regional recurrence of medullary thyroid carcinoma
-
Fiore D, Rubello D, Casara D, Pelizzo MR, Franchi A, Muzzio PC. Role of CT/111In-octreotide SPECT digital fusion imaging in the localization of loco-regional recurrence of medullary thyroid carcinoma. Minerva Chir. 2004;59: 295-9.
-
(2004)
Minerva Chir
, vol.59
, pp. 295-299
-
-
Fiore, D.1
Rubello, D.2
Casara, D.3
Pelizzo, M.R.4
Franchi, A.5
Muzzio, P.C.6
-
13
-
-
82455175241
-
Detection by SPECT-CT scan with (99m) Tc-(V) DMSA of bone metastases in patient with medullary thyroid cancer
-
De Bonilla-Damia A, Calvo-Moron C, De La Riva-Perez PA, Iglesias-Jerez R, Molina-Mora M, Castro-Montano J. Detection by SPECT-CT scan with (99m) Tc-(V) DMSA of bone metastases in patient with medullary thyroid cancer. Rev Esp Med Nucl. 2011;30: 365-7.
-
(2011)
Rev Esp Med Nucl
, vol.30
, pp. 365-367
-
-
De Bonilla-Damia, A.1
Calvo-Moron, C.2
De La Riva-Perez, P.A.3
Iglesias-Jerez, R.4
Molina-Mora, M.5
Castro-Montano, J.6
-
14
-
-
34748865440
-
Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary hyroid carcinoma
-
Czepczynski R, Parisella MG, Kosowicz J,Mikolajczak R, Ziemnicka K, Gryczynska M, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary hyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34: 1635-45.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
, pp. 1635-1645
-
-
Czepczynski, R.1
Parisella, M.G.2
Kosowicz, J.3
Mikolajczak, R.4
Ziemnicka, K.5
Gryczynska, M.6
-
15
-
-
0031668864
-
Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological indings
-
Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hor G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological indings. Eur J Nucl Med. 1998;25: 1277-83.
-
(1998)
Eur J Nucl Med
, vol.25
, pp. 1277-1283
-
-
Adams, S.1
Baum, R.P.2
Hertel, A.3
Schumm-Draeger, P.M.4
Usadel, K.H.5
Hor, G.6
-
16
-
-
0034756055
-
Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study
-
Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001;28: 1671-6.
-
(2001)
Eur J Nucl Med
, vol.28
, pp. 1671-1676
-
-
Diehl, M.1
Risse, J.H.2
Brandt-Mainz, K.3
Dietlein, M.4
Bohuslavizki, K.H.5
Matheja, P.6
-
17
-
-
35948994121
-
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels
-
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 007;92: 4185-90.
-
J Clin Endocrinol Metab
, vol.7
, Issue.92
, pp. 4185-4190
-
-
Giraudet, A.L.1
Vanel, D.2
Leboulleux, S.3
Auperin, A.4
Dromain, C.5
Chami, L.6
-
18
-
-
36849090954
-
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy
-
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92: 4590-7.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 4590-4597
-
-
Oudoux, A.1
Salaun, P.Y.2
Bournaud, C.3
Campion, L.4
Ansquer, C.5
Rousseau, C.6
-
19
-
-
34248594179
-
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated alcitonin levels
-
Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated alcitonin levels. J Nucl Med. 2007;48: 501-7.
-
(2007)
J Nucl Med
, vol.48
, pp. 501-507
-
-
Ong, S.C.1
Schoder, H.2
Patel, S.G.3
Tabangay-Lim, I.M.4
Doddamane, I.5
Gonen, M.6
-
20
-
-
41949099184
-
The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective tudy
-
Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective tudy. Eur J Surg Oncol. 2008;34: 581-6.
-
(2008)
Eur J Surg Oncol
, vol.34
, pp. 581-586
-
-
Rubello, D.1
Rampin, L.2
Nanni, C.3
Banti, E.4
Ferdeghini, M.5
Fanti, S.6
-
21
-
-
77951768869
-
Role of [(18) F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer
-
Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18) F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31: 567-75.
-
(2010)
Nucl Med Commun
, vol.31
, pp. 567-575
-
-
Skoura, E.1
Rondogianni, P.2
Alevizaki, M.3
Tzanela, M.4
Tsagarakis, S.5
Piaditis, G.6
-
22
-
-
78049336593
-
The prognostic value of 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma
-
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP,Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010;12: 547-53.
-
(2010)
Mol Imaging Biol
, vol.12
, pp. 547-553
-
-
Bogsrud, T.V.1
Karantanis, D.2
Nathan, M.A.3
Mullan, B.P.4
Wiseman, G.A.5
Kasperbauer, J.L.6
-
23
-
-
0033625019
-
Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific ositioning labeling in positron emission tomography
-
Sundin A, Eriksson B, Bergstrom M, Bjurling P, Lindner KJ, Oberg K, et al. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific ositioning labeling in positron emission tomography. Nucl Med Biol. 2000;27: 33-41.
-
(2000)
Nucl Med Biol
, vol.27
, pp. 33-41
-
-
Sundin, A.1
Eriksson, B.2
Bergstrom, M.3
Bjurling, P.4
Lindner, K.J.5
Oberg, K.6
-
24
-
-
0021047386
-
Striatal dopamine metabolism in living monkeys examined by positron emission tomography
-
Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280: 169-71.
-
(1983)
Brain Res
, vol.280
, pp. 169-171
-
-
Garnett, S.1
Firnau, G.2
Nahmias, C.3
Chirakal, R.4
-
25
-
-
0027018649
-
Uptake and utilization of [beta-11C]5-hydroxytryptophan in human brain studied by positron emission tomography
-
Reibring L,Agren H,Hartvig P, Tedroff J, Lundqvist H, Bjurling P, et al. Uptake and utilization of [beta-11C]5-hydroxytryptophan in human brain studied by positron emission tomography. Psychiatry Res. 1992;45: 215-25.
-
(1992)
Psychiatry Res
, vol.45
, pp. 215-225
-
-
Reibring, L.1
Agren, H.2
Hartvig, P.3
Tedroff, J.4
Lundqvist, H.5
Bjurling, P.6
-
26
-
-
0034746433
-
18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels
-
Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28: 64-71.
-
(2001)
Eur J Nucl Med
, vol.28
, pp. 64-71
-
-
Hoegerle, S.1
Altehoefer, C.2
Ghanem, N.3
Brink, I.4
Moser, E.5
Nitzsche, E.6
-
27
-
-
67349208753
-
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: Comparison with 18F-FDG PETCT
-
Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PETCT. Eur Radiol. 2009;19: 1425-34.
-
(2009)
Eur Radiol
, vol.19
, pp. 1425-1434
-
-
Beheshti, M.1
Pocher, S.2
Vali, R.3
Waldenberger, P.4
Broinger, G.5
Nader, M.6
-
28
-
-
34748868457
-
Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-Omethyl- 6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma
-
Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-Omethyl- 6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34: 1604-9.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
, pp. 1604-1609
-
-
Beuthien-Baumann, B.1
Strumpf, A.2
Zessin, J.3
Bredow, J.4
Kotzerke, J.5
-
29
-
-
65549141729
-
The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors
-
Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16: 255-65.
-
(2009)
Endocr Relat Cancer
, vol.16
, pp. 255-265
-
-
Kauhanen, S.1
Seppanen, M.2
Ovaska, J.3
Minn, H.4
Bergman, J.5
Korsoff, P.6
-
30
-
-
42049103697
-
18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Elation to tumor differentiation
-
Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: elation to tumor differentiation. J Nucl Med. 2008;49: 524-31.
-
(2008)
J Nucl Med
, vol.49
, pp. 524-531
-
-
Koopmans, K.P.1
De Groot, J.W.2
Plukker, J.T.3
De Vries, E.G.4
Kema, I.P.5
Sluiter, W.J.6
-
31
-
-
77949270173
-
Dual PET/CT with (18) F-DOPA and (18) FFDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging
-
Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18) F-DOPA and (18) FFDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol. 2010;36: 414-21.
-
(2010)
Eur J Surg Oncol
, vol.36
, pp. 414-421
-
-
Marzola, M.C.1
Pelizzo, M.R.2
Ferdeghini, M.3
Toniato, A.4
Massaro, A.5
Ambrosini, V.6
-
32
-
-
77949273307
-
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA ET/CT) for detecting pheochromocytoma
-
Luster M, KargesW, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA ET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37: 484-93.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 484-493
-
-
Luster, M.1
Kargesw Zeich, K.2
Pauls, S.3
Verburg, F.A.4
Dralle, H.5
-
33
-
-
72949085037
-
PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[( 18) F]F-L-DOPA
-
Pestourie C, Theze B, Kuhnast B, Le Helleix S, Gombert K, Dolle F, et al. PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18) F]F-L-DOPA. Eur J Nucl Med ol Imaging. 2010;37: 58-66.
-
(2010)
Eur J Nucl Med Ol Imaging
, vol.37
, pp. 58-66
-
-
Pestourie, C.1
Theze, B.2
Kuhnast, B.3
Le Helleix, S.4
Gombert, K.5
Dolle, F.6
-
34
-
-
77952340573
-
Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma
-
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20: 527-33.
-
(2010)
Thyroid
, vol.20
, pp. 527-533
-
-
Luster, M.1
Karges, W.2
Zeich, K.3
Pauls, S.4
Verburg, F.A.5
Dralle, H.6
-
35
-
-
83755162307
-
Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer
-
Kauhanen S, Schalin-Jantti C, Seppanen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52: 1855-63.
-
(2011)
J Nucl Med
, vol.52
, pp. 1855-1863
-
-
Kauhanen, S.1
Schalin-Jantti, C.2
Seppanen, M.3
Kajander, S.4
Virtanen, S.5
Schildt, J.6
-
36
-
-
84859795319
-
Sequential 18F-FDG and 18-F-DOPA PET/CT in recurrent medullary thyroid cancer (MTC)
-
Marzola MC, Ferdeghini M, Rampin L, Banti L, Grassetto G, Cittadin S, et al. Sequential 18F-FDG and 18-F-DOPA PET/CT in recurrent medullary thyroid cancer (MTC) . J Nucl Med. 2010;51 Suppl 2: 71.
-
(2010)
J Nucl Med
, vol.51
, Issue.SUPPL. 2
, pp. 71
-
-
Marzola, M.C.1
Ferdeghini, M.2
Rampin, L.3
Banti, L.4
Grassetto, G.5
Cittadin, S.6
-
37
-
-
77953928471
-
The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy
-
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51: 875-82.
-
(2010)
J Nucl Med
, vol.51
, pp. 875-882
-
-
Srirajaskanthan, R.1
Kayani, I.2
Quigley, A.M.3
Soh, J.4
Caplin, M.E.5
Bomanji, J.6
-
38
-
-
0026378464
-
Somatostatin receptors and somatostatin content in medullary thyroid carcinomas
-
Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64: 567-73.
-
(1991)
Lab Invest
, vol.64
, pp. 567-573
-
-
Reubi, J.C.1
Chayvialle, J.A.2
Franc, B.3
Cohen, R.4
Calmettes, C.5
Modigliani, E.6
-
39
-
-
0035726431
-
Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid
-
Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol Oxf. 2001;54: 641-9.
-
(2001)
Clin Endocrinol Oxf
, vol.54
, pp. 641-649
-
-
Papotti, M.1
Kumar, U.2
Volante, M.3
Pecchioni, C.4
Patel, Y.C.5
-
40
-
-
36749090076
-
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial
-
Iten F, Muller B, Schindler C, Rochlitz C, Oertli D,Macke HR, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13: 6696-702.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6696-6702
-
-
Iten, F.1
Muller, B.2
Schindler, C.3
Rochlitz, C.4
Oertli Dmacke, H.R.5
-
41
-
-
78650564928
-
Localization of medullary thyroid carcinoma after surgery using (11) C-methionine PET/CT: Comparison with (18) F-FDG PET/CT
-
Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, et al. Localization of medullary thyroid carcinoma after surgery using (11) C-methionine PET/CT: comparison with (18) F-FDG PET/CT. Endocr J. 2010;57: 1045-54.
-
(2010)
Endocr J
, vol.57
, pp. 1045-1054
-
-
Jang, H.W.1
Choi, J.Y.2
Lee, J.I.3
Kim, H.K.4
Shin, H.W.5
Shin, J.H.6
-
42
-
-
77953239940
-
The surgical management of medullary thyroid cancer
-
Dackiw AP. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am. 2010;43: 365-74.
-
(2010)
Otolaryngol Clin North Am
, vol.43
, pp. 365-374
-
-
Dackiw, A.P.1
-
43
-
-
77957947626
-
Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers
-
Tai D, Poon D. Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. J Oncol. 2011;2011: pii 398564
-
(2011)
J Oncol
, vol.2011
, pp. 398564
-
-
Tai, D.1
Poon, D.2
-
44
-
-
77955214443
-
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer
-
Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39: 775-83
-
(2010)
Pancreas
, vol.39
, pp. 775-783
-
-
Chen, H.1
Sippel, R.S.2
O'Dorisio, M.S.3
Vinik, A.I.4
Lloyd, R.V.5
Pacak, K.6
-
45
-
-
79251524248
-
Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma
-
Biermann K, Biersack HJ, Sabet A, Janzen V. Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nucl Med. 2011;41: 139-48.
-
(2011)
Semin Nucl Med
, vol.41
, pp. 139-148
-
-
Biermann, K.1
Biersack, H.J.2
Sabet, A.3
Janzen, V.4
-
46
-
-
79960906082
-
Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer
-
Divgi C. Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med. 2011;41: 369-73.
-
(2011)
Semin Nucl Med
, vol.41
, pp. 369-373
-
-
Divgi, C.1
-
47
-
-
79959742655
-
Updates in the management of medullary thyroid cancer
-
Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol. 2011;9: 391-4.
-
(2011)
Clin Adv Hematol Oncol
, vol.9
, pp. 391-394
-
-
Hu, M.I.1
-
48
-
-
66149139452
-
From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors
-
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1: 122S-50S.
-
(2009)
J Nucl Med
, vol.50
, Issue.SUPPL. 1
-
-
Wahl, R.L.1
Jacene, H.2
Kasamon, Y.3
Lodge, M.A.4
-
49
-
-
79851504300
-
Metabolic imaging allows early prediction of response to vandetanib
-
Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, et al. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med. 2011;52: 231-40.
-
(2011)
J Nucl Med
, vol.52
, pp. 231-240
-
-
Walter, M.A.1
Benz, M.R.2
Hildebrandt, I.J.3
Laing, R.E.4
Hartung, V.5
Damoiseaux, R.D.6
-
50
-
-
79957707824
-
Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: A useful tool for patient risk stratification
-
Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol. 2011;164: 971-6.
-
(2011)
Eur J Endocrinol
, vol.164
, pp. 971-976
-
-
Mian, C.1
Pennelli, G.2
Barollo, S.3
Cavedon, E.4
Nacamulli, D.5
Vianello, F.6
|